trial

Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

NCTId NCT00166322
as of 2026-07-01
at a glance
· Completed
Enrollment 35 (actual)
Primary completion 2007-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Status
Completed
Enrollment
35 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2004-01
Primary completion
2007-12
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Sponsors

Investigators

2
Oliver Pogarell, MDPrincipal Investigator
Klaus Tatsch, MDPrincipal Investigator

Sites

2 total
Munich, GermanyMunich, Germany

Facts & assertions

4 sourced
Enrollment
35
Phase
NA
Primary Completion Date
2007-12
Status
COMPLETED
relationships
The graph out of here